Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Industry News (Clinical Trials)
Three New In Vivo Gene Therapy Trials Initiated
November 20th, 1995
Introgen Therapeutics, Inc., Austin, Texas, announced that researchers at the University of Texas M.D. Anderson Cancer Center, Houston, have initiated three new in vivo gene therapy studies for the treatment of cancer. Introgen, which maintains a broad, exclusive license to numerous technologies developed by key scientists at M.D. Anderson, now has the largest in vivo cancer portfolio in the field of gene therapy. The study researchers have injected the first patients ever with a p53/adenoviral gene therapy product for the treatment of non-resectable and resectable head and neck cancer and non-small cell lung cancer (NSCLC). "Our...
Source: Cancer Weekly (1995-11-20)
|
